Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Sep 17, 2024 5:37pm

48 Views

Post# 36227965

RE:RE:RE:RE:New Press Release - Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025

So we are facing uncertainty about their ability to exist for the next 6 months I guess. What will Marathon say about this. Will they loose Egrifta patients if there is a shortage. Anyway again it's a surprise to them it seems and to us poor shareholders that are about to get poorer thanks to this unpredictable event it seems.

<< Previous

Bullboard Posts

Next >>

Here are three global stocks you should watch